Andrew M. Blakely, M.D.
Dr. Blakely is a surgical oncologist specializing in peritoneal surface and retroperitoneal malignancies. A primary focus of his research is to develop novel treatment approaches and modalities to improve pre-operative treatment of peritoneal carcinomatosis.
1) peritoneal surface malignancy, 2) gastroenteropancreatic neuroendocrine tumor,
3) soft tissue sarcoma, 4) adrenocortical carcinoma
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis from Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesOpen - Not yet Recruiting Summary Not Yet Available. Call Referral Contact.NCI Protocol ID NCI-21-C-0012Investigator Andrew M. Blakely, M.D.Share this trial: Referral Contacts
Contact Name Phone Number Cathleen Hannah 240.858.7006
Peritoneal malignancies may arise from various organs, including but not limited to the colon, appendix, stomach, ovary, or adrenal gland. However, peritoneal tumor deposits tend to be relatively resistant to traditional intravenous systemic chemotherapy regimens that are otherwise effective for disease involving other sites, such as the liver or lungs. Administration of intraperitoneal chemotherapy allows much higher chemotherapeutic drug levels to be achieved in the peritoneal cavity, with far less systemic absorption and toxicity than if given intravenously at the same dose. However, intraperitoneal chemotherapy is only effective after cytoreductive surgery, where all disease >2.5 mm has been completely removed or ablated. Unfortunately, many patients with peritoneal carcinomatosis have high burdens of disease, which may preclude optimal cytoreduction or lead to such debilitation that extensive surgical resection would not be tolerated by the patient.
Dr. Blakely’s research primarily focuses on developing treatment strategies that bring the potential benefits of pre-operative therapy to patients with peritoneal surface malignancies. Neoadjuvant intraperitoneal chemotherapy administration may reduce peritoneal surface disease burden, which in turn facilitates or even obviates subsequent cytoreductive surgery. In addition, for patients experiencing symptomatic malignant ascites, intraperitoneal chemotherapy alone can effectively palliate unresectable patients.
Selected Key Publications
- Tissue Engineering Part C Methods. 21(7): 737-746, 2015. [ Journal Article ]
A Collaborative Surgical Approach to Upper and Lower Abdominal Cytoreductive Surgery in Ovarian Cancer.Journal of Surgical Oncology. 118(1): 121-126, 2018. [ Journal Article ]
- Histopathology. 72(3): 405-413, 2018. [ Journal Article ]
American College of Surgeons National Surgical Quality Improvement Program as a Quality-Measurement Tool for Advanced Cancer Patients .Annals of Palliative Medicine. 4(4): 200-206, 2015. [ Journal Article ]
- Journal of Surgical Oncology. 110(6): 615-655, 2015. [ Journal Article ]
Dr. Blakely completed a Bachelor of Science in Biomedical Engineering followed by medical school at Drexel University. He went on to general surgery residency at Brown University. During residency, he spent two years of dedicated research time at the Center for Biomedical Engineering developing a device for tissue engineering applications. That work then led to a National Science Foundation grant and a patent. Dr. Blakely then completed his fellowship in Complex General Surgical Oncology at City of Hope National Medical Center.
|Position||Degree Required||Contact Name||E-mail Address|
|Clinical Fellow - Surgical Oncology, Fellowship, Training||M.D. or equivalent||Joanna Lamotfirstname.lastname@example.org|
|Wendy Barrios-Aquino||Patient Care Coordinator (Contr.)|
|Claudia Espinoza||Patient Care Coordinator (Contr.)|
|Cathleen Hannah R.N.||Research Nurse|
|Stacy Joyce PA-C||Physician Assistant (Contr.)|
|Audra Satterwhite R.N.||Research Nurse|